Browse Category

NYSE:WNS News 8 July 2025

AI Today: Breakthroughs, Bias, Regulation & the Road Ahead – July 8, 2025 Update

AI Today: Breakthroughs, Bias, Regulation & the Road Ahead – July 8, 2025 Update

The European Union’s AI Act will be fully enforced by mid-2026, establishing strict rules for high-risk AI applications across member states. Capgemini agreed to acquire WNS Holdings for $3.3 billion to accelerate autonomous AI for enterprise operations. At the BRICS summit, UN Secretary-General António Guterres urged multilateral AI governance and announced plans for an independent UN AI advisory body. Ukraine’s Diia app now resolves 52% of support requests using AI, signaling rapid digital-government transformation. The Velvet Sundown, an AI-generated music group, surpassed 1 million Spotify streams in a month. Isomorphic Labs, Google’s DeepMind spin-off, will begin human trials for AI-developed

Stock Market Today

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

Disney stock ends week higher after Friday bounce — what to watch for DIS next week

7 February 2026
Disney shares closed up 3.6% at $108.70 Friday, recovering from earlier losses as U.S. stocks rallied and the Dow topped 50,000. Investors are watching Super Bowl streaming economics and Disney’s CEO transition, with Josh D’Amaro set to take over at the March 18 meeting. Disney reported quarterly revenue of $25.98 billion and adjusted EPS of $1.63, while segment operating income fell 9% to $4.6 billion.
Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

Novo Nordisk stock: Class B shares face Monday test after FDA squeeze forces Hims to pull $49 Wegovy copycat

7 February 2026
Novo Nordisk Class B shares closed up 5.3% at 295.50 Danish crowns in Copenhagen after Hims & Hers said it would stop offering a compounded pill version of Wegovy following U.S. regulatory warnings. The move came after Novo called the Hims product “illegal mass compounding” and threatened legal action. Shares had fallen nearly 8% Thursday after Hims launched the pill. Trading resumes Monday.
Go toTop